NuVue Therapeutics, Inc. is a medical device, diagnostics, and drug delivery company with an initial focus on accurate diagnosis and targeted treatment of liver, pancreatic, and other hard-to-treat soft-tissue cancers. The company designs diagnostic products to give a bright, clear image of biopsy needles in real-time during procedures and to accurately mark sites for further imaging and/or biopsies. It also designs therapeutic products to avoid the toxic effects of systemic chemotherapy by providing targeted delivery of free and encapsulated drugs and thermal effects directly into tumors.
Delcath Systems, IncDelcath Systems is a commercial-stage interventional oncology company developing and providing liver-directed therapies for primary and metastatic liver cancers. Its Hepatic Delivery System uses vascular isolation, focused drug delivery and filtration to administer high-dose treatment directly to the liver, with HEPZATO KIT™ marketed in the United States and CHEMOSAT® in Europe. The company’s clinical work began with uveal melanoma and is expanding into other liver-dominant cancers.New York, NY
Molecular Targeting Technologies, IncMolecular Targeting Technologies, Inc. develops targeted radiopharmaceuticals and molecular-imaging technologies for cancer and other diseases, alongside research reagents such as CellVue® and NeuroVue® fluorescent dyes. Based in West Chester, Pennsylvania, the company’s work spans clinical-stage platforms including EBTATE® and EvaThera, as well as custom affinity absorbents and laboratory products. Its leadership brings extensive experience in radiopharmaceutical development, nuclear medicine, fluorescent chemistry, and biopharmaceutical regulation.325412WEST CHESTER, PA
Ultrasonic Medical Mapping, IncBethesda-based Ultrasonic Medical Mapping develops radiation-free cancer-detection technology, adapting a mature method from defense and aerospace testing for medical use. Its patented system is focused on finding pancreatic tumors earlier and at smaller sizes than existing imaging and non-imaging technologies, and the company has built a preclinical prototype for technical validation. UMM is now working toward clinical testing with hospital and clinical partners.BETHESDA, MD